The assays presented in this work could serve as a companion diagnostic to select patients for such a therapy since mutations in the RAS and PIK3CA genes, together amounting to 27% in MI-BC, might prohibit the effect of FGFR3 inhibitors. This evidence concerns the gene FGFR3 and breast cancer.